Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.3652W HIGH $35.83
Volume
5.95 M
Value Traded
14.57 M
Short % Float
22.84%
Days to Cover
11.3
-14.38%Week
-47.58%1 Month
-49.07%3 Month
-49.36%6 Month
+11.38%5 Year
+11.38%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
777.83 M
EPS (TTM)
-3.32
P/E Ratio
-
Ent. Value
404.71 M
Total Shares
49.31 M
Float Shares
37.00 M
Insiders
24.95%
Institutions
78.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AVBP Catalyst Timeline
Dated clinical, regulatory and corporate events for ArriVent BioPharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ArriVent BioPharma, Inc.
112Total events
9Upcoming
27Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
◆Late-BreakerARR-217Presentation
ARR-217 first-in-human Phase 1 data selected as ESMO 2026 late-breaking oral presentation (LBA34)
gastrointestinal cancerssource ↗
◆Oral PresentationARR-217Presentation
Oral presentation of first-in-human MRG007 (ARR-217) data in advanced solid tumors at ESMO 2026
locally advanced or metastatic solid tumorssource ↗
▲Topline ReadoutARR-217Clinical Data
Initial Phase 1 results for ARR-217: 44.8% ORR at 6mg/kg in late-line CRC
colorectal cancer and other gastrointestinal cancerssource ↗
▲PublicationFirmonertinibApprovedPresentation
Cancer Cell publication of FURTHER Phase 1b results of firmonertinib in EGFR PACC-mutant NSCLC
EGFR PACC-mutant non-small cell lung cancer (NSCLC)source ↗
▲First Patient DosedARR-002Trial
First patient dosed with ARR-002 in Phase 1 trial in the U.S.
ovarian and endometrial cancersource ↗
●Safety Data UpdateFirmonertinibApprovedClinical Data
FURVENT safety data consistent with previous firmonertinib studies
first-line EGFR exon 20 insertion mutant non-squamous NSCLCsource ↗
▼Primary Endpoint MissedFirmonertinibApprovedClinical Data
FURVENT Phase 3 trial did not meet primary endpoint of PFS by BICR
first-line EGFR exon 20 insertion mutant non-squamous NSCLCsource ↗
▲Secondary Endpoint DataFirmonertinibApprovedClinical Data
Clinical benefit observed with secondary endpoints in FURVENT
first-line EGFR exon 20 insertion mutant non-squamous NSCLCsource ↗
▲Trial InitiationARR-217Trial
ARR-217 advanced into Phase 1b dose optimization at 5 and 6 mg/kg Q3W
gastrointestinal cancerssource ↗
▲Trial InitiationARR-217Trial
Phase 1b dose optimization initiated for ARR-217
gastrointestinal malignanciessource ↗
▲Partnership / LicenseARR-002Corporate
Greater China license agreement with Allist for ARR-002
▲Partnership / LicenseARR-002Corporate
Exclusive licensing agreement with Allist for ARR-002 in Greater China
ovarian and endometrial cancersource ↗
▲Trial InitiationARR-002Trial
First patient dosing with ARR-002 expected in Q3 2026
ovarian and endometrial cancerssource ↗
◆Dose Finding UpdateARR-217Trial
Initiate Phase 1 dose optimization for ARR-217
gastrointestinal malignanciessource ↗
◆Topline ReadoutFirmonertinibApprovedClinical Data
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC
first-line EGFR exon 20 insertion mutant NSCLCsource ↗
▲IND ClearanceARR-002IND
FDA IND clearance for ARR-002 in May 2026
ovarian and endometrial cancerssource ↗
◆Poster PresentationPresentation
Poster presentation on Exatecan Payload-Based ADCs with AQUALINK platform at AACR 2026
◆Poster PresentationFirmonertinibApprovedPresentation
Poster presentation on discovery and characterization of firmonertinib at AACR 2026
EGFR exon 20 insertion mutant non-small cell lung cancersource ↗
◆Oral PresentationARR-002Presentation
Oral presentation by Aarvik on ARR-002 at AACR Clinical Research Mini Symposium
ovarian and endometrial cancerssource ↗
◆Poster PresentationARR-002Presentation
Poster presentation of AV-P138-ADC (ARR-002) at AACR 2026
ovarian and endometrial cancerssource ↗
◆Poster PresentationARR-002Presentation
Poster presentation on ARR-002 (AV-P138-ADC) at AACR 2026
ovarian and endometrial cancerssource ↗
●Poster PresentationFirmonertinibApprovedPresentation
Preclinical data for firmonertinib presented at AACR
EGFR mutant NSCLCsource ↗
●Poster PresentationARR-002Presentation
Preclinical data for ARR-002 presented at AACR
ovarian and endometrial cancerssource ↗
●Oral PresentationARR-002Presentation
Oral presentation of ARR-002 data at AACR Clinical Research Mini Symposium
ovarian and endometrial cancerssource ↗
▲First Patient DosedARR-217Trial
First patient dosed with ARR-217 in Phase 1
gastrointestinal malignanciessource ↗
▲FDA ApprovalFirmonertinibApprovedFDA Decision
NMPA accelerated approval in China for second-line EGFR exon 20 insertion mutations
second-line EGFR exon 20 insertion mutations NSCLCsource ↗
◆Topline ReadoutFirmonertinibApprovedClinical Data
Topline data expected from Phase 3 FURVENT trial
non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutationssource ↗
▲Preclinical PoCARR-002Preclinical
Preclinical data for ARR-002 presented at AACR 2026
ovarian and endometrial cancersource ↗
▲First Patient DosedFirmonertinibApprovedTrial
First patient dosed in global pivotal Phase 3 ALPACCA trial of firmonertinib for first-line EGFR PACC mutant NSCLC
EGFR PACC mutant non-small cell lung cancersource ↗
▲First Patient DosedFirmonertinibApprovedTrial
First patient enrollment expected in global registrational Phase 3 ALPACCA trial
non-small cell lung cancer (NSCLC) with EGFR PACC mutationssource ↗
▲Oral PresentationFirmonertinibApprovedPresentation
Final analysis of firmonertinib monotherapy data from Phase 1b FURTHER trial presented at WCLC 2025
non-small cell lung cancer (NSCLC) harboring EGFR PACC mutationssource ↗
◆Oral PresentationFirmonertinibApprovedPresentation
Present final PACC Phase 1b data at World Conference on Lung Cancer
EGFR PACC mutant NSCLCsource ↗
▼Equity OfferingCorporate
Proposed $75 million public offering of common stock and pre-funded warrants
▲First Patient DosedFirmonertinibApprovedTrial
Enroll first patient in global pivotal Phase 3 PACC study
EGFR PACC mutant NSCLCsource ↗
◆R&D DayFirmonertinibApprovedPresentation
Virtual investor event on firmonertinib path forward for EGFR PACC mutant NSCLC
EGFR PACC mutant non-small cell lung cancersource ↗
◆Oral PresentationFirmonertinibApprovedPresentation
Virtual webinar presenting interim firmonertinib monotherapy data from FURTHER trial
EGFR PACC mutant non-small cell lung cancersource ↗
▲Topline ReadoutFirmonertinibApprovedClinical Data
Positive interim firmonertinib monotherapy data from FURTHER trial
EGFR PACC mutant non-small cell lung cancersource ↗
▲Enrollment CompleteFirmonertinibApprovedTrial
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations
first-line NSCLC harboring EGFR exon 20 insertion mutationssource ↗
Past FDA Catalysts and PDUFA Decisions
How AVBP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-25 | ARR-217 (MRG007), CDH17-directed exatecan ADC | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 6%
Micro Cap(rank 40 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Firmonertinib Small moleculeNCT05364073 | Non-Small-Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 920 | Dec 31, 2026 | ||||||
| Firmonertinib Small moleculeNCT05607550 | Metastatic Non-Small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 398 | Feb 15, 2028 | ||||||
| MRG007 Small moleculeNCT07066657 | Locally Advanced or Metastatic Solid Tumors | Phase 1 | RECRUITING | 572 | Dec 1, 2030 | ||||||
| ARR-002 Small moleculeNCT07755436 | Ovarian Cancer | Phase 1 | RECRUITING | 180 | May 1, 2029 | ||||||
| AST2818 Small moleculeMarketedNCT03941340 | Undisclosed | Phase 1 | COMPLETED | 22 | Sep 6, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every AVBP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ARR-217 | gastrointestinal cancers | Phase 1 | 2026-10-25 | ORR 6mg/kg: 44.8%; DCR 6mg/kg: 93.1%; ORR 4mg/kg and higher: 34.2%; DCR 4mg/kg and higher: 91.8%; Grade 3 or higher TRAE: 30.1%Read More | ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HILLHOUSE INVESTMENT MANAGEMENT, LTD.10% Owner | Sell | -555,555 3,929,117 held | $23.37 | 12/10/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in AVBP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1.9 % (35.7 %) | 105.17 M | 3.03 M |
AVBP Institutional Ownership Trends
AVBP Short Interest
Shares sold short, counted twice a month.
22.84%
Short % of Float
of tradable shares sold short
8.5M
Shares Sold Short
-3.6% vs prior count
11.3 Very high
Days to Cover
trading days of normal volume to buy every short share back
751.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AVBP ranks across every disease it competes in
Competitive Position is a premium feature
See how AVBP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAVBP News
AVBP▼ -26.2%today
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
ArriVent BioPharma announced promising Phase 1 data for ARR-217, a CDH17-targeted ADC, at the ESMO Congress 2026. The study showed a 44.8% objective response rate in heavily pretreated colorectal cancer patients. The drug demonstrated a manageable safety profile, leading to plans for a Phase 1b dose optimization study in 2027.
Read more →AVBP▼ -26.2%today
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
ArriVent BioPharma announced that initial Phase 1 data for its CDH17-targeted ADC, ARR-217, will be presented at the ESMO Congress 2026. The presentation is scheduled for October 25, 2026, and will focus on the drug's safety and efficacy in patients with gastrointestinal cancers. A virtual webinar will also be held to discuss the findings.
Read more →AVBP▲ +7.7%on this news
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
ArriVent BioPharma announced the publication of Phase 1b results for firmonertinib, a targeted therapy for EGFR PACC-mutant non-small cell lung cancer (NSCLC). The findings indicate firmonertinib's potential as a first-line treatment, showcasing high response rates and significant intracranial activity. The company is currently enrolling patients in a global Phase 3 trial to further evaluate its efficacy.
Read more →AVBPArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
ArriVent BioPharma has announced the dosing of its first patient in a Phase 1 trial for ARR-002, a novel tetravalent antibody-drug conjugate targeting MUC16 and NaPi2b for ovarian and endometrial cancer. This marks a significant expansion of their clinical pipeline. The dual-targeting mechanism aims to improve treatment efficacy in solid tumors. Additionally, a licensing agreement with Shanghai Allist Pharmaceuticals will facilitate development in Greater China.
Read more →AVBP▼ -47%on this news
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib for treating EGFR exon 20 insertion mutant NSCLC did not meet its primary endpoint of progression-free survival. However, secondary endpoints showed some clinical benefit, including a trend towards improved overall survival. The safety profile remained consistent with prior studies, with no new safety signals identified.
Read more →AVBPArriVent BioPharma Reports Second Quarter 2026 Financial Results
ArriVent BioPharma reported its second quarter 2026 financial results, highlighting significant advancements in its clinical pipeline. The company anticipates topline Phase 3 data for firmonertinib in treating EGFR exon 20 insertion mutant NSCLC in the second half of 2026. Additionally, ARR-217 has progressed to Phase 1b dose optimization, while ARR-002 is set to begin dosing its first patient in Q3 2026. The company maintains a solid financial position with $373.1 million in cash.
Read more →AVBPArriVent BioPharma Reports First Quarter 2026 Financial Results
ArriVent BioPharma reported its Q1 2026 financial results, highlighting significant advancements in its clinical pipeline. The company anticipates pivotal Phase 3 data for firmonertinib in mid-2026 and has received IND clearance for ARR-002, a dual-targeting ADC. Financially, ArriVent maintains a robust cash position to support operations through late 2027.
Read more →AVBPArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
ArriVent BioPharma has received FDA clearance for its investigational drug ARR-002, a tetravalent antibody-drug conjugate targeting MUC16 and NaPi2b. This ADC aims to treat ovarian and endometrial cancers, showing promising preclinical results in terms of efficacy and safety. A Phase 1 trial is expected to begin in the second half of 2026.
Read more →AVBPAarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
Aarvik Therapeutics will present at the AACR Annual Meeting 2026, showcasing its ADC capabilities. The company will feature two posters and an oral presentation, focusing on its MUTTA™ and AQUALINK™ platforms. These presentations aim to demonstrate advancements in cancer therapies, particularly for ovarian and endometrial cancers, through innovative dual-target ADCs.
Read more →AVBPArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
ArriVent BioPharma announced two poster presentations at the 2026 AACR Annual Meeting, focusing on firmonertinib, an EGFR inhibitor, and ARR-002, a dual-target ADC. Firmonertinib shows significant potential against EGFR mutations, while ARR-002 exhibits superior efficacy in ovarian cancer models. Both candidates are advancing towards clinical evaluation.
Read more →AVBPArriVent BioPharma Reports Full Year 2025 Financial Results
ArriVent BioPharma reported its financial results for the year ending December 31, 2025, highlighting significant progress in the development of firmonertinib for treating uncommon EGFR mutations in NSCLC. The CEO noted that firmonertinib is advancing towards potential registration, with pivotal trial data expected in mid-2026. The company's portfolio also includes an antibody-drug conjugate targeting gastrointestinal cancers, reflecting its commitment to addressing high unmet medical needs in oncology. The organization is well-positioned with a strong balance sheet and a cash runway expected to last into Q3 2027.
Read more →AVBPArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
ArriVent BioPharma has initiated the global pivotal Phase 3 ALPACCA trial, dosing the first patient with firmonertinib for treating EGFR PACC mutant non-small cell lung cancer (NSCLC). This trial aims to evaluate firmonertinib against current treatment options, addressing a significant unmet need in this patient population. The study's endpoints include overall response rate and progression-free survival.
Read more →AVBPArriVent BioPharma Reports Third Quarter 2025 Financial Results
ArriVent BioPharma reported strong financial results for Q3 2025, highlighting progress in its firmonertinib program for EGFR-mutant non-small cell lung cancer (NSCLC). The company is conducting pivotal Phase 3 trials for both PACC mutant and exon 20 insertion mutant NSCLC. Their lead candidate firmonertinib, recently granted FDA Breakthrough Therapy Designation, aims to fulfill significant unmet needs in these underserved populations. Additionally, the firm is advancing its antibody-drug conjugate (ADC) pipeline, projecting further developments toward clinical trials.
Read more →AVBPArriVent Appoints Brent S. Rice as Chief Commercial Officer
ArriVent BioPharma has appointed Brent S. Rice as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology sector. Rice's prior role at Autolus Therapeutics involved leading global commercialization strategies. His expertise is expected to strengthen ArriVent's commercial foundation as the company approaches the potential approval of firmonertinib for treating EGFR mutant non-small cell lung cancer.
Read more →AVBPArrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
ArriVent BioPharma presented final data from a Phase 1b trial showing firmonertinib achieved a 16.0-month median progression-free survival in first-line EGFR PACC mutant lung cancer patients. The drug also demonstrated a 68.2% confirmed overall response rate and cleared circulating tumor DNA in most treated individuals. The company expects to enroll the first patient in its pivotal Phase 3 ALPACCA study in the second half of 2025.
Read more →AVBPArriVent BioPharma Reports Second Quarter 2025 Financial Results
ArriVent BioPharma reported a net loss of $95.8 million for the first half of 2025. The company held $254.5 million in cash and investments as of June 30, 2025. This balance is expected to fund operations through mid-2027. The firm also dosed the first patient in a Phase 1 study for its ADC candidate ARR-217.
Read more →AVBPArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
ArriVent BioPharma has announced that topline data from its pivotal Phase 3 FURVENT study on firmonertinib for first-line NSCLC with EGFR exon20 insertion mutations is expected in early 2026. The study, which has completed enrollment, aims to evaluate progression-free survival compared to standard chemotherapy. Firmonertinib has also received FDA Breakthrough Therapy Designation for this indication.
Read more →AVBPArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
ArriVent BioPharma has announced the pricing of a public offering, raising approximately $75 million through the sale of common stock and pre-funded warrants. The offering is managed by Goldman Sachs, Citigroup, and Guggenheim Securities, with a closing date expected around July 3, 2025. Proceeds will be used to further develop firmonertinib and other pipeline projects.
Read more →AVBPArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
ArriVent BioPharma, Inc. has announced its intention to conduct a public offering of $75 million in common stock and pre-funded warrants. The proceeds will be utilized to advance its lead therapeutic candidate, firmonertinib, amidst other pipeline initiatives. Major financial firms, including Goldman Sachs and Citigroup, are managing the offering, which is contingent on market conditions. This move reflects the company's strategy to enhance its capabilities in the biopharmaceutical sector.
Read more →AVBP▼ -9.6%on this news
Arrivent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal
Arrivent BioPharma has announced positive interim results from its Phase 1b study of firmonertinib for treating EGFR PACC mutant non-small cell lung cancer (NSCLC). The study reported a median progression-free survival of 16 months and notable central nervous system activity, with a significant proportion of patients achieving complete and overall responses. Based on these encouraging findings, Arrivent plans to advance firmonertinib into a global pivotal Phase 3 study, with patient enrollment expected to begin in the second half of 2025. The company aims to address unmet medical needs in this underserved patient population.
Read more →About ArriVent BioPharma, Inc.
Headquarters18 CAMPUS BLVD., NEWTOWN SQUARE, PA, 19073-3269
BIOPHARMAWATCH ELITE PLUS
Trade the next AVBP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime